Dr. Pardeep Nijhawan FRCPC, M.D. Net Worth

Dr. Pardeep Nijhawan FRCPC, M.D. biography

Dr. Pardeep Nijhawan FRCPC, M.D. is the CEO, Company Sec. & Director at Edesa Biotech.

What is the salary of Dr D?

As the CEO und Company Sec. & Director of Edesa Biotech, the total compensation of Dr D at Edesa Biotech is $498,773. There are no executives at Edesa Biotech getting paid more.

How old is Dr D?

Dr D is 50, he's been the CEO und Company Sec. & Director of Edesa Biotech since . There are 1 older and 1 younger executives at Edesa Biotech. The oldest executive at Edesa Biotech, Inc. is Kathi Niffenegger CPA, CPA, 64, who is the Chief Financial Officer.

What's Dr D's mailing address?

Pardeep's mailing address filed with the SEC is C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM, A6, L3R 5H6.

Insiders trading at Edesa Biotech

Over the last 5 years, insiders at Edesa Biotech have traded over $856,596 worth of Edesa Biotech stock and bought 247,412 units worth $776,447 . The most active insiders traders include Der Velden Peter Lumira Cap..., Pardeep Pardeep Nijhawan Me... und Jennifer M Chao. On average, Edesa Biotech executives and independent directors trade stock every 50 days with the average trade being worth of $73,455. The most recent stock trade was executed by Pardeep Pardeep Nijhawan Me... on 25 March 2024, trading 5,000 units of EDSA stock currently worth $20,000.

What does Edesa Biotech do?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Edesa Biotech executives and stock owners

Edesa Biotech executives and other stock owners filed with the SEC include:

• Dr. Pardeep Nijhawan FRCPC, M.D.,
  CEO, Company Sec. & Director
• Dr. Michael J. Brooks M.B.A., Ph.D.,
  Pres
• Kathi Niffenegger CPA, CPA,
  Chief Financial Officer
• Rajan Puri,
  Sr. VP of Manufacturing
• Gary Koppenjan,
  VP of Investor Relations & Communications
• Patrick Marshall,
  
• Stephen Lemieux,
  Chief Financial Officer
• Joan Chypyha,
  
• Charles V Olson,
  
• Lorin K Johnson,
  
• Carlo Sistilli,
  
• Kathi Niffenegger,
  Chief Financial Officer
• Der Velden Peter Lumira Cap...,
  
• Jennifer M Chao,
  
• Frank R. Oakes,
  
• Pardeep Pardeep Nijhawan Me...,
  Chief Executive Officer
• Paul William Pay,
  
• Der Velden Peter Van,
  
• Sean Arthur Mac Donald,
  
• Michael J Brooks,
  President
• Pardeep Nijhawan,
  Chief Executive Officer